Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2000

View Archived Issues

Pamiteplase, a novel t-PA, offers possibility of single bolus injection

Effects of COX-2 inhibition on blood pressure and leukocyte adherence explored

Human Genome Sciences updates Q1 developments

Amgen's late-stage product candidates continue to advance

Aronex updates clinical trial programs

Myriad Genetics awarded important gene patent

Angiotensin II inhibition reduces early atherogenesis in monkeys

Suramin therapy shows benefits in hormone-refractory prostate cancer

PowderJect reports progress towards HIV DNA vaccine

Use of epinastine as cough suppressant or for enhancing effects of other antitussives

P&G research team focuses on new treatments for hair loss

Antisense modulators of RhoA, RhoB and RhoC under study at Isis

Synthesis, activity and therapeutic use of new LTA4 hydrolase inhibitors

Aventis prepares new treatments for obesity, diabetes

Inhibitors of protein farnesyltransferase patented by Schering-Plough

5-HT1D receptor-selective diazabicyclooctanes designed at Merck

Evidence presented at AUA meeting for safety and efficacy of new gene therapy in prostate cancer

New gene therapy technique for brain cancer prolongs survival in mice

CollaGenex files new MAA, enters marketing agreement for Periostat tablets

Prototype cancer vaccine demonstrates efficacy

VaxGen's AIDS vaccine trials making good progress

Data presented at AUA meeting validate efficacy of SAAND compounds for cancer

European research team discovers new class of antiviral nucleosides

BMS-204352: a novel maxi-K channel opener effective in rat models of acute focal stroke

AAN news: trial determines doses of Antegren for multiple-dose studies in MS

Overseas clinical pipeline updated by Toyama

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.